Exagen reports comparative study in Lupus confirms Avise effectiveness

Exagen announced new robust, real-world evidence confirming AVISE testing enables decisive clinical action in the differential diagnosis for lupus. The Complement Activation Products vs. Standard ANA Testing: Treatment Outcomes, Diagnosis, and Economic Impact in Systemic Lupus Erythematosus, or CAPSTONE, study is the largest comparative utility study in lupus diagnosis and was published in the Journal of Managed Care & Specialty Pharmacy. The study leveraged multiple external databases encompassing electronic health records and linked insurance claims data on nearly 50,000 patient tests with AVISE or standard of care labs from hundreds of rheumatologists across the U.S., comparing diagnosis, treatment, and cost of care outcomes for new patients tested with AVISE Lupus and those tested with a traditional ANA approach, including specific autoantibodies. The findings revealed that the AVISE Lupus test is more clinically effective, both for patients who test positive and those who test negative, as compared to the current standard of care.